X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES ABBOTT INDIA SUVEN LIFESCIENCES/
ABBOTT INDIA
 
P/E (TTM) x 19.1 40.3 47.4% View Chart
P/BV x 3.7 10.7 34.8% View Chart
Dividend Yield % 0.6 0.6 95.0%  

Financials

 SUVEN LIFESCIENCES   ABBOTT INDIA
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
ABBOTT INDIA
Mar-18
SUVEN LIFESCIENCES/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2516,110 4.1%   
Low Rs1553,996 3.9%   
Sales per share (Unadj.) Rs49.11,552.2 3.2%  
Earnings per share (Unadj.) Rs9.7188.8 5.1%  
Cash flow per share (Unadj.) Rs11.4196.4 5.8%  
Dividends per share (Unadj.) Rs1.5055.00 2.7%  
Dividend yield (eoy) %0.71.1 67.9%  
Book value per share (Unadj.) Rs60.3796.6 7.6%  
Shares outstanding (eoy) m127.2821.25 599.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.13.3 126.9%   
Avg P/E ratio x20.926.8 78.0%  
P/CF ratio (eoy) x17.825.7 69.2%  
Price / Book Value ratio x3.46.3 53.1%  
Dividend payout %15.429.1 53.0%   
Avg Mkt Cap Rs m25,825107,376 24.1%   
No. of employees `0001.13.3 32.3%   
Total wages/salary Rs m6133,937 15.6%   
Avg. sales/employee Rs Th5,832.69,929.3 58.7%   
Avg. wages/employee Rs Th571.51,185.1 48.2%   
Avg. net profit/employee Rs Th1,153.81,207.7 95.5%   
INCOME DATA
Net Sales Rs m6,25332,985 19.0%  
Other income Rs m2331,170 19.9%   
Total revenues Rs m6,48534,155 19.0%   
Gross profit Rs m1,9825,245 37.8%  
Depreciation Rs m213162 131.6%   
Interest Rs m4638 121.2%   
Profit before tax Rs m1,9556,215 31.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7182,203 32.6%   
Profit after tax Rs m1,2374,012 30.8%  
Gross profit margin %31.715.9 199.3%  
Effective tax rate %36.735.4 103.7%   
Net profit margin %19.812.2 162.6%  
BALANCE SHEET DATA
Current assets Rs m5,62222,655 24.8%   
Current liabilities Rs m1,1686,681 17.5%   
Net working cap to sales %71.248.4 147.1%  
Current ratio x4.83.4 142.0%  
Inventory Days Days8165 125.7%  
Debtors Days Days3629 123.2%  
Net fixed assets Rs m3,325835 397.9%   
Share capital Rs m127213 59.9%   
"Free" reserves Rs m7,54716,715 45.1%   
Net worth Rs m7,67416,928 45.3%   
Long term debt Rs m140-   
Total assets Rs m9,13524,162 37.8%  
Interest coverage x43.2163.7 26.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.71.4 50.1%   
Return on assets %14.016.8 83.8%  
Return on equity %16.123.7 68.0%  
Return on capital %26.036.9 70.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,066369 1,374.6%   
Fx outflow Rs m2,0013,807 52.6%   
Net fx Rs m3,065-3,438 -89.1%   
CASH FLOW
From Operations Rs m6991,527 45.8%  
From Investments Rs m-6-2,148 0.3%  
From Financial Activity Rs m-577-1,024 56.3%  
Net Cashflow Rs m116-1,646 -7.1%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 7.9 -  
FIIs % 0.0 0.1 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 17.1 213.5%  
Shareholders   37,287 18,270 204.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare SUVEN LIFESCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Jalan Committee Recommendations; US-China Trade Worries; Key Q1FY20 Results and Top Stocks in Action(Pre-Open)

On Thursday, the Indian share markets fell sharply in late trade as US-China trade worries dragged global peers.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 18, 2019 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS